ARISTADA
Active substance: aripiprazole lauroxil
INJECTION, SUSPENSION, EXTENDED RELEASE · ARIPIPRAZOLE LAUROXIL 662 mg/2.4mL
United StatesActive
Marketing holder: Alkermes, Inc.
Verified 2026-10-09 · openFDA NDC
- Source: openFDA NDC
- Countries with the substance registered: 1
Composition
- ARIPIPRAZOLE LAUROXIL · 662 mg/2.4mL
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208d-79cb-7a60-88b0-818a81c84aa0,01a12096-e8c9-7114-b1db-2d849f214ca1,01a12096-e8ca-7a93-b152-c6b1b38e9e13,01a12099-1b7d-7afc-ace0-725c4399cbcb,01a1209b-9135-7ed0-a5b2-a1e04b0a8b0d;count=5 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 65757-402
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAMUSCULAR
Sources
- product · openFDA NDC · 65757-402 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 65757-402 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 65757-402 · Verified 2026-10-09 · open in source